Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CIN 2 Clear all
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 22, 2026, 10:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilots of Self-Collection for HPV DNA Detection

NCT00342511
View directory record Official record
Conditions
HPV
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Tucson, Arizona • East Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Recruiting Phase 2 Interventional

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

NCT06210854
View directory record Official record
Conditions
HPV Infection
Interventions
pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses)
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Not applicable Interventional

UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia

NCT00003598
View directory record Official record
Conditions
Cervical Cancer, Precancerous/Nonmalignant Condition
Interventions
tretinoin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03721978
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Matched Placebo, CELLECTRA™-5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jul 22, 2026, 10:39 AM EDT
Completed No phase listed Observational

IMproved PRactice Outcomes and Value Excellence in Colposcopy

NCT02185599
View directory record Official record
Conditions
High Grade Cervical Intraepithelial Neoplasia
Interventions
DySIS
Device
Lead sponsor
DySIS Medical Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
7,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
46
States / cities
Scottsdale, Arizona • Gainesville, Florida • Jacksonville, Florida + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

NCT01022346
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Placebo, RO5217790
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
43
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 1 Interventional

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

NCT00278434
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Zoledronate, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

NCT04154488
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
St. Petersburg, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional

Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection

NCT01094132
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Multispectral Digital Colposcope (MDC)
Device
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Female only
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Brooklyn, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 22, 2026, 10:39 AM EDT
Recruiting Phase 2 Interventional

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744
View directory record Official record
Conditions
CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions
Artesunate vaginal insert, Placebo vaginal insert
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
25 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 22, 2026, 10:39 AM EDT
Not listed Phase 2 Interventional

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00060099
View directory record Official record
Conditions
Precancerous Condition
Interventions
HspE7
Biological
Lead sponsor
Dana-Farber/Brigham and Women's Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

NCT00685412
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
Interventions
motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 2 Interventional

Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

NCT00701870
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
24
States / cities
Alhambra, California • Anaheim, California • Burbank, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening

NCT01550783
View directory record Official record
Conditions
Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Health Status Unknown, Human Papillomavirus Infection, Low Grade Cervical Squamous Intraepithelial Neoplasia, Stage 0 Cervical Cancer
Interventions
Cervical Papanicolaou Test, Cytology Specimen Collection Procedure, Questionnaire Administration, Screening Method
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Female only
Enrollment
1,335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 22, 2026, 10:39 AM EDT
Withdrawn Phase 2 Interventional

Carotenoid Rich Diet in Treating Cervical Dysplasia

NCT00003094
View directory record Official record
Conditions
Cervical Cancer
Interventions
preventative dietary intervention
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 22, 2026, 10:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples

NCT04423679
View directory record Official record
Conditions
Human Papilloma Virus, Cervical Cancer, CIN 2/3
Interventions
Evalyn Brush
Device
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 69 Years · Female only
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 4 Interventional

A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

NCT00289029
View directory record Official record
Conditions
CIN
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

NCT01304524
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
VGX 3100, Placebo, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 22, 2026, 10:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Jul 22, 2026, 10:39 AM EDT